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Abstract
AIM: To examine cytokeratin-18 (CK-18) and caspase-
cleaved CK-18 expression in tumours and correlate with 
clinicopathological outcomes including tumour regres-
sion grade (TRG) response.
METHODS: Formalin-fixed human gastro-oesophageal 
cancers were constructed into tissue microarrays. The 
first set consisted of 122 gastric/gastro-oesophageal 
cancer cases not exposed to neoadjuvant chemotherapy 
and the second set consisted of 97 gastric/gastro-
oesophageal cancer cases exposed to pre-operative 
platinum-based chemotherapy. Expression of CK-18 and 
caspase-cleaved CK-18 was investigated using immuno-
histochemistry. 
RESULTS: CK18 was commonly expressed in gastro-
oesophageal tumours (92.6%). Fifty-six point seven 
percent of tumours previously exposed to neoadjuvant 
chemotherapy were positive for caspase-cleaved CK-18 
expression compared to only 24.6% of tumours not 
previously exposed to neoadjuvant chemotherapy (P  = 
0.009). In patients who received neoadjuvant chemo-
therapy, caspase-cleaved cytokeratin-18 expression 
correlated with favourable TRG response (TRG 1, 2 or 3, 
P  = 0.043). 
CONCLUSION: This is the largest study to date of 
CK-18 and caspase-cleaved CK-18 expression in gastro-
oesophageal tumours. We provide the first evidence 
that caspase-cleaved CK-18 predicts tumour regression 
with neoadjuvant chemotherapy. 
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Neoadjuvant platinum-based chemotherapy followed by 
surgery is the standard of  care for patients with gastro-
oesophageal adenocarcinoma[1,2]. However, there is an ur-
gent need to develop predictive markers to individualize 
patient therapy[3]. We have recently shown that tumour 
regression grade (TRG) is a marker of  histopathological 
response and tumour down-staging in tumours receiving 
neoadjuvant chemotherapy[4]. TRG was defined as per 
Mandard’s criteria[5]. TRG1 (complete regression) showed 
absence of  residual cancer and fibrosis extending through 
the different layers of  the oesophageal wall; TRG2 was 
characterised by the presence of  rare residual cancer cells 
scattered through the fibrosis; TRG3 was characterised 
by an increase in the number of  residual cancer cells but 
fibrosis predominated; TRG4 showed residual cancer 
outgrowing fibrosis; and TRG5 was characterised by the 
absence of  regressive changes[5]. In patients who received 
neoadjuvant chemotherapy (CS group), 46.7% of  gas-
tric/gastro-oesophageal junction adenocarcinomas and 
45.5% of  lower third oesophageal adenocarcinomas had 
TRG 1, 2 or 3 compared to 13.7% in patients who did 
not receive neoadjuvant chemotherapy but proceeded to 
primary surgery. In the CS group, responders (TRG 1, 2 
or 3) showed significant tumour down-staging [early ypT-
stage disease (P = 0.002)]. In gastric cancers specifically, 
additional associations were seen with negative nodal 
disease (P = 0.044) and absence of  vascular invasion (P = 
0.027)[4]. More recently, we have also demonstrated that 
favourable tumour regression predicts better clinical out-
comes in patients receiving neoadjuvant chemotherapy in 
gastro-oesophageal adenocarcinomas[6]. 
The anticancer activity of  chemotherapeutic agents is 
directly related to the induction of  apoptosis in tumours. 
Whilst the apoptotic pathway is complex, the intrinsic 
mitochondrial pathway is the predominant apoptotic 
pathway in cancer cells. In the intrinsic pathway, the mi-
tochondrial release of  cytochrome c activates caspase-9, 
which in turn activates caspase-3 and caspase-7[7,8]. Among 
the several cellular substrates of  the capsases, members of  
the cytokeratin family, including cytokeratin-18 (CK-18), 
contribute to cellular collapse and apoptosis. Caspase-
cleaved CK-18 is a specific marker of  epithelial cell death 
and correlates with apoptosis in gastrointestinal epithelial 
cancers[9-11]. 
In the current study we have evaluated full length 
CK-18 and caspase-cleaved CK-18 protein expression 
using immunohistochemistry. We show for the first time 
that caspase-cleaved CK-18 expression in tumours cor-
relates with histopathological tumour regression in early 
stage gastro-oesophageal adenocarcinomas. 
MATERIALS AND METHODS
Patients
We identified patients referred to our centre with resect-
able gastric, gastro-oesophageal junction (GOJ) and lower 
third oesophageal adenocarcinomas between January 
2001 and May 2008. GOJ tumours were defined as per 
Siewert’s classification[12]. The Union for International 
Cancer Control TNM staging system for oesophageal 
and gastric cancer was used in this study. The study was 
approved by the Ethics Committee of  Nottingham Uni-
versity Hospitals.
Construction of tissue micro-array
Tissue micro-arrays (TMAs) were constructed. In brief, 
HE-stained slides (5 µm) were used to identify and mark 
out representative areas of  viable tumour tissue. Then 
0.6 mm-diameter needle core biopsies from the relevant 
areas of  corresponding paraffin-embedded blocks were 
placed at defined coordinates in the recipient paraffin 
array blocks using a tissue microarrayer (Beecher Instru-
ments, Sun Prairie, WI). Array blocks were constructed 
at a density of  80-150 cores per array. Two broad sets of  
TMA blocks were constructed. An array set of  97 patient 
cores to include gastric and gastro-oesophageal tumours 
that had received neoadjuvant chemotherapy and an array 
set of  122 cores of  patients who had received no neo-
adjuvant chemotherapy were constructed. These TMA 
blocks were constructed in triplicate, each containing one 
sample from a different region of  the tumour.
Immunohistochemistry
A standard streptavidin-biotin complex technique was 
used. In brief, 5 µm TMA sections were deparaffinised 
with xylene and rehydrated through graded alcohol. 
Endogenous peroxidase was blocked with 0.3% hydro-
gen peroxide in methanol for 20 min. Antigen retrieval 
was carried out by microwave treatment of  the slides 
in sodium citrate buffer (pH 6) for 10 min at 750 W 
followed by 10 min at 300 W. The slides were rinsed 
in phosphate buffer saline (PBS) and incubated with 
Vectastain blocking serum diluted in PBS to block non-
specific absorption. The slides were incubated for 30 min 
with the primary antibody M30 to detect caspase-cleaved 
CK-18 (Peviva, Bromma, Sweden) at a dilution of  1:75 
and primary antibody M6 to detect full length CK-18 
(Peviva, Bromma, Sweden) at a dilution of  1:150 at room 
temperature. After washing with PBS, sections were in-
cubated with secondary antibody (Vectastain) for 30 min 
followed by avidin-biotin complex for a further 30 min. 
3-3’ Diaminobenzidine tetrahydochloride was used as a 
chromogen. All sections were counterstained with Gill’
s haematoxylin, dehydrated and mounted using DPX (a 
mixture of  disterene, plasticizer, and xylene; Sigma). 
Evaluation of staining 
Evaluation of  staining was performed with the observer 
blinded to the corresponding clinicopathological data. For 
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full length CK-18 expression, cytoplasmic expression in 
cancer cells was considered positive. For caspase-cleaved 
CK-18 expression, TMA cores from tumour showing any 
positively stained apoptotic cells were considered posi-
tive. Caspase-cleaved CK-18 positive apoptotic cells were 
counted in TMA cores and the total number of  positive 
cells from each tumour was taken as the number of  posi-
tive cells. 
Statistical analysis
All statistical analyses were carried out using SPSS pack-
age (version 15 for Windows, SPSS, Inc.). Associations 
between categorical variables were examined using cross-
tabulation and the Pearson χ 2 test. Kaplan Meier curves 
were derived to assess disease-specific survival, and the 
significance of  differences in disease-specific survival 
between groups was calculated using the log-rank test. 
Patients whose death related to their oesophago-gastric 
cancer were considered in the disease-specific survival 
calculations. This was determined by death certification 
entries. Deaths resulting from non-oesophago-gastric 
cancer-related causes were censored. Survival rates were 
calculated from the date of  diagnosis until the 13th Janu-
ary 2009, when any remaining survivors were censored 
and Kaplan Meier curves were plotted. In all cases, P < 
0.05 was considered statistically significant. 
RESULTS
Patient demographics
There were 2 groups of  patients: those who received ne-
oadjuvant chemotherapy (neoadjuvant group) and those 
who underwent primary surgery only (primary group). 
There were 97 patients in the neoadjuvant group with 
a median age of  64 years; 76% (n = 74) were male and 
51.5% (n = 50) of  cases were T3 tumours. There were 
122 cases in the primary group with a median age of  
74.5 years; 75.4% (n = 92) were male and 53.2% (n = 65) 
had T3 tumours. Patients in the primary surgery group 
did not receive any adjuvant chemotherapy after surgery. 
In the neoadjuvant group, 78% of  patients had received 
all the planned three cycles of  neoadjuvant ECF/ECX 
chemotherapy (adenocarcinomas) and 96.4% had re-
ceived all the planned two cycles of  neoadjuvant CF 
chemotherapy (squamous cell carcinomas). Of  the pa-
tients who received all three cycles of  ECF/ECX chemo-
therapy, 42% went on to receive a further three cycles 
of  ECF/ECX chemotherapy. There was no significant 
difference between the primary surgery group and the 
perioperative chemotherapy group (gastric/GOJ) with 
regards to T stage [T2 (33.6% vs 29.8%), T3 (53.2% vs 
51.5%)] and N stage [N0 (26.2% vs 31.9%), > N0 (73.8% 
vs 68.1%)]. Only adenocarcinomas were included in the 
immunohistochemical and survival analyses in this study 
(Table 1).
Full length cytokeratin-18 expression 
All 122 tumours in the primary surgery group were avail-
able for CK-18 analyses. One hundred and thirteen tu-
mours stained positive for CK-18 (92.6%) (Figure 1A) 
and 9 cores were negative for CK-18 expression. There 
was no statistically significant correlation between tumour 
differentiation, T stage, N stage, vascular/perineural inva-
sion, resection margin involvement and full length CK-18 
expression in tumours.
Caspase-cleaved cytokeratin-18 expression 
All tumours were suitable for caspase-cleaved CK-18 ex-
pression analyses (Figure 1B). In tumours previously ex-
posed to neoadjuvant chemotherapy (neoadjuvant TMA, n 
= 97), 56.7% of  tumours (55/97) were positive compared 
to 24.6% (30/122) of  tumours not previously exposed 
to neoadjuvant chemotherapy (primary TMA). This was 
statistically significant (P = 0.009). The mean total number 
of  caspase-cleaved CK-18 positive cancer cells per tumour 
was 4.16 in the neoadjuvant group (range: 1-92) compared 
to 2.7 in the primary surgery group (range: 1-51). 
We have previously demonstrated that TRG as as-
sessed using Mandard’s criteria is a useful tool to assess 
response to neoadjuvant chemotherapy in gastro-oesopha-
geal adenocarcinomas; favourable TRG correlated with tu-
mour down-staging in that study[4]. In the current study we 
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Total number of patients 97 122
Median age (yr) 64      74.5
Sex
Male 74 (76)    92 (75.4)
Female 23 (24)    30 (24.6)
T stage
   T1    6 (6.1)  12 (9.8)
   T2    29 (29.8)    41 (33.6)
   T3    50 (51.5)    65 (53.2)
   T4    8 (8.2)    4 (3.2)
   TX 1 (1)
N stage
   N0    31 (31.9)    32 (26.2)
   ≥ N1    66 (68.1)    90 (73.8)
M stage
   M0    97 (100) 122 (100)
   M1 -  -
Tumour type
   Adenocarcinoma    83 (85.5) 122 (100)
   Squamous cell carcinoma    12 (12.3) -
   Adenosquamous 2 (2) -
Site of tumour
   Gastric    20 (20.6) 122 (100)
   GOJ    47 (48.4) -
   Lower third of oesophagus    36 (37.1) -
Surgery
   Total gastrectomy 22 70
   Partial gastrectomy   5 39




   Alive    47 (48.4) 47 (38)
   Dead    50 (51.6) 75 (62)
GOJ: Gastro-oesophageal junction.  
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and caspase-cleaved CK-18 positivity were observed. 
Regarding patients who had not received neoadjuvant 
chemotherapy, Kaplan Meier plot showed that in pa-
tients whose tumours stained positive for caspase-cleaved 
CK-18, a longer disease-specific survival was observed 
compared to patients whose tumours were negative (mean 
84 mo vs 51 mo, P = 0.003) (Figure 2). However, in pa-
tients who had received neoadjuvant chemotherapy, no 
statistically significant differences were observed (mean 
37.3 mo vs 41.6 mo, P = 0.975) (Figure 2).
Those factors found to be significant in univariate 
analyses were also included in a multivariate logistic re-
gression analysis to estimate the independent effect of  
each factor after adjusting for the contributions of  other 
factors. There was no one factor in the cohort of  patients 
studied that showed significance on multivariate analysis 
(Table 3).
DISCUSSION
The ability to predict response to chemotherapy and in-
dividualize patient treatment is a high priority in gastro-
oesophageal adenocarcinomas. Whilst the role of  multi-
evaluated whether caspase-cleaved CK-18 expression cor-
related with TRG. We found that 43.6% of  tumours that 
were positive for caspase-cleaved CK18 also had a favour-
able tumour response (TRG 1-3) compared to 23.8% that 
were negative for caspase-cleaved CK-18 expression (Table 
2). This was statistically significant (P = 0.043). There was 
no statistically significant correlation between tumour 
differentiation, T stage, N stage, vascular/perineural inva-
sion, resection margin involvement and caspase-cleaved 
CK-18 positivity.
Clinicopathological correlations were also observed 
in tumours not exposed to neoadjuvant chemotherapy. 
Well-differentiated tumours were more likely to be cas-
pase-cleaved CK-18 positive (62.5%) compared to poor- 
and moderately-differentiated tumours which were only 
positive in 23.6% and 19% of  tumours respectively (P = 
0.031). However, no differences between T, N stage, vas-
cular/perineural invasion, resection margin involvement 
Figure 1  Immunohistochemical staining of full length cytokeratin-18 and 
caspase-cleaved cytokeratin-18. A: Immunohistochemical staining of full 
length cytokeratin-18 (CK-18) showing strong cytoplasmic staining; B: Immuno-
histochemical staining for caspase-cleaved CK-18. Cores from tumour showing 
positively-stained apoptotic cells. Original magnification × 100; insets × 400. 
B
A
Table 2  Caspase-cleaved cytokeratin-18 and tumour regression 
in tumours exposed to neoadjuvant chemotherapy  n  (%)
Caspase-cleaved CK-18 TRG1, TRG2, TRG3 TRG4, TRG5 Total 
Negative 10 (23.8) 32 (76.2) 42 (100)
Positive 24 (43.6) 31 (56.4) 55 (100)
Total 34 (35.1) 63 (64.9) 97 (100)
CK-18: Cytokeratin-18; TRG: Tumour regression grade.
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Figure 2  Kaplan Meier curves representing the relationship between 
caspase-cleaved cytokeratin-18 and disease-specific survival. A: In months 
from time of diagnosis in patients who received primary surgery only; B: In pa-
tients who received neoadjuvant chemotherapy. 
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modality therapy in improving patient outcomes is well 
established, these treatments are toxic and have a consid-
erable impact on patient morbidity. In the United King-
dom, neoadjuvant chemotherapy followed by surgery is 
routinely offered to patients who are fit with no signifi-
cant co-morbidities. Accordingly, these patients generally 
tend to be young and can tolerate toxic chemotherapy. 
Patients considered not suitable for chemotherapy are 
usually elderly with significant co-morbidities. Moreover, 
until 2006 in the United Kingdom, the standard treat-
ment for patients with early stage gastro-oesophageal 
adenocarcinoma was surgery only and patients were not 
routinely offered adjuvant chemotherapy. With the pub-
lication of  results from a large United Kingdom trial of  
perioperative chemotherapy[1], neoadjuvant chemotherapy 
was established as a standard treatment option for pa-
tients. This is reflected in the differences in mean age 
between the two groups in our study. 
 In the current study we have evaluated the potential 
role of  full length CK-18 and caspase-cleaved CK-18 as 
biomarkers in gastro-oesophageal adenocarcinomas. To 
evaluate the prognostic significance of  full length CK-18 
in gastro-oesophageal adenocarcinomas, we first evalu-
ated CK-18 expression in tumours not exposed to neo-
adjuvant chemotherapy (n = 122). We found that CK-18 
was commonly expressed in tumours. This is consistent 
with a previously reported study[13]. Although Xu et al[13] 
demonstrated that CK18 mRNA expression correlated 
with lymph node metastasis and tumour differentiation in 
gastric cancer, we were unable to demonstrate any posi-
tive clinicopathological correlations in our study. 
Caspase-cleaved CK-18 has recently emerged as a prom-
ising marker of  apoptosis in gastrointestinal cancers[11]. We 
therefore evaluated caspase-cleaved CK-18 expression 
in gastro-oesophageal adenocarcinomas. Fifty-six point 
seven percent of  tumours previously exposed to neoad-
juvant chemotherapy were positive for caspase-cleaved 
CK-18 expression, compared to only 24.6% of  tumours 
not previously exposed to neoadjuvant chemotherapy 
(P = 0.009). This provides direct evidence that chemo-
therapy exposure leads to apoptosis-induced increased 
caspase-cleaved CK-18 expression in gastro-oesophageal 
tumours. We then demonstrated, for the first time, that 
the caspase-cleaved CK-18 expression correlated well 
with favourable tumour regression in patients receiving 
neoadjuvant chemotherapy (P = 0.043). Factors found to 
be significant in univariate analyses were not significant 
in a multivariate logistic regression analysis. This may be 
because the current study is a small retrospective study 
and a larger prospective study is required to confirm our 
observations. However, our study provides evidence that 
caspase-cleaved CK-18 may be a promising predictive bi-
omarker in gastro-oesophageal adenocarcinomas. Moreo-
ver, our study also supports a rational hypothesis for 
evaluating serial blood caspase-cleaved CK18 secretion, 
using a recently developed assay[11,14,15], as a promising 
non-invasive biomarker in operable gastro-oesophageal 
adenocarcinomas where patients routinely receive three 
cycles of  platinum-based neoadjuvant chemotherapy[1,2]. 
In a recent study of  advanced colorectal cancer, serum 
levels of  caspase-cleaved CK18 were significantly higher 
in patients who responded to chemotherapy compared to 
those who did not[11]. Similar results were also reported 
in advanced colorectal, oesophageal and gastric adeno-
carcinoma patients receiving palliative chemotherapy[16]. 
Although these results are promising, whether tumour 
tissue and serum caspase CK-18 levels are related to each 
other is not clear. Moreover, whether similar results could 
be achieved in early stage gastro-oesophageal adenocar-
cioma patients receiving neoadjuvant chemotherapy is an 
area of  ongoing investigation in our laboratory. 
We also made interesting clinicopathological observa-
tions in tumours not exposed to chemotherapy. Caspase-
cleaved CK18 expression correlated with better differen-
tiation and improved survival in this group. Although the 
reason for this unexpected finding is not clear, whether 
host immune factors such as lymphocytic infiltration 
could contribute to cancer cell death is  currently un-
known and is an area of  ongoing investigation. 
In summary, we have conducted a study of  full length 
CK-18 and caspase-cleaved CK-18 expression in gastro-
oesophageal cancer. We provide evidence that caspase-
cleaved CK-18 is a promising predictive biomarker in patients 
who receive platinum-based neoadjuvant chemotherapy.
ACKNOWLEDGMENTS
The authors wish to thank Dr. Stewart Martin, Labora-
tory of  Molecular Oncology, University of  Nottingham, 
Table 3  Univariate and multivariate analyses showing 
predictive factors for disease-specific and overall survival in 
neoadjuvant and surgery only groups




   Caspase-cleaved CK-18 positivity   0.975   0.865 1.32
   TRG 1-3 vs 4-5   0.038   0.136   0.109
   Tumour diff. (well/mod vs poor)   0.087   0.101 0.32
   T stage (T1, 2 and 3, 4) 0.07 0.09   0.101
   N stage (N0 and > N1)   0.106   0.124 0.23
   M stage (M0 and > M0) 0.23 0.14 1.72
   Vascular invasion 0.87 0.76 0.86
   Perineural invasion 1.32   1.455 1.76
   Resection margin involvement 2.34 1.98 0.24
Surgery only group
   Caspase-cleaved CK-18 positivity   0.003   0.668 0.10
   TRG 1-3 vs 4-5 0.87   0.003 0.23
   Tumour diff. (well/mod vs poor) 0.39 0.34 0.21
   T stage (T1, 2 and 3, 4) 0.04 0.08 0.19
   N stage (N0 and > N1) 0.16 0.10 0.43
   M stage (M0 and > M0) 1.27 1.64 1.99
   Vascular invasion 1.98 1.67 1.34
   Perineural invasion 1.56 1.99 2.43
   Resection margin involvement 0.34 0.25 0.34
DSS: Disease-specific survival; OS: Overall survival; CK-18: Cytokeratin-18; 
TRG: Tumour regression grade; diff.: Differentiation.
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Background
Neoadjuvant chemotherapy followed by surgery is a standard treatment option 
in patients with early stage gastro-oesophageal adenocarcinomas. However, 
only 40% of patients respond to chemotherapy. There is an urgent need to de-
velop predictive biomarkers.
Research frontiers
Development of a serum biomarker test that can predict response to chemo-
therapy is highly desirable in gastro-oesophageal adenocarcinomas.
Innovations and breakthroughs
Cytokeratin-18 (CK-18) is commonly expressed in epithelial tumours. Caspase-
cleaved CK-18 is expressed in cancer cells undergoing apoptosis following 
chemotherapy. Caspase-cleaved CK-18 is also secreted by tumour cells and 
can be evaluated using a blood test. In early stage gastrooesophageal cancers, 
the authors show that caspase-cleaved CK-18 is prevalent in tumour tissue 
following chemotherapy and that this correlates with tumour regression. The 
study suggests that serum testing of caspase-cleaved CK-18 may be feasible 
to predict response in early stage gastro-oesophageal adenocarcinomas. 
Applications
A prospective study of serial serum testing of caspase-cleaved CK-18 elevation 
and correlation with tumour response to chemotherapy is required to evaluate 
CK-18 as a promising predictive biomarker in early stage gastro-oesophageal 
adenocarcinomas. 
Terminology
CK-18 is widely expressed in epithelial cancers. Caspase-cleaved CK-18: in 
epithelial cells undergoing apoptosis, caspase-cleaved CK-18 is expressed and 
can be detected by immunohistochemistry.
Peer review
This is a study to evaluate whether caspase-cleaved CK-18 can predict re-
sponse to chemotherapy in gastro-oesophageal adenocarcinomas receiving 
neoadjuvant chemotherapy. Data presented here support a rational hypothesis 
to test if secretion of caspase-cleaved CK-18 in blood can be used as a marker 
of response to chemotherapy in patients.
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